Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia.

Like Comment
The efficacy and safety of thrombopoietin-receptor agonists (TRAs) in elderly patients with primary immune thrombocytopenia (ITP) is uncertain. In 384 ITP patients treated with TRAs when aged ≥60 years, we investigated TRAs response and switch, thrombotic/hemorrhagic risk, and sustained responses off-treatment (SROT). After 3 months, 82.5% and 74.3% of eltrombopag and romiplostim-treated patients achieved a response, respectively (p=0.09); 66.7% maintained the response (median follow-up: 2.7 years). Eighty-five (22.2%) patients switched to the alternative TRA; while no cross-toxicity was observed, 83.3% of resistant patients had a response after the switch. During TRA, 34 major thromboses (3 fatal) and 14 major hemorrhages (none fatal) occurred in 18 and 10 patients, respectively, and were associated with thrombosis history (SHR: 2.04, p=0.05) and platelet count <20x109/L at TRA start (SHR: 1.69, p=0.04), respectively. A recurrent event occurred in 15.6% of patients surviving thrombosis, in all cases but one during persisting TRA treatment (incidence rate: 7.7 per 100 patient-years). All recurrences occurred in the absence of adequate antithrombotic secondary prophylaxis. Sixty-two (16.5%) responding patients discontinued TRA; 53 (13.8%) patients maintained SROT, which was associated with TRA discontinuation in complete response (p<0.001). Very old age (≥75, 41.1%) was associated with more frequent TRAs start in persistent/acute phase but not with response or thrombotic/hemorrhagic risk. TRAs are effective in elderly ITP patients, with no fatal haemorrhages and with SROT in a significant portion of patients; in patients with thrombosis history caution is warranted and a careful risk/benefit balance should be carried out.


View the full article @ Blood


Get PDF with LibKey
Authors: Francesca Palandri, Elena Rossi, Daniela Bartoletti, Antonietta Ferretti, Marco Ruggeri, Elisa Lucchini, Valentina Carrai, Wilma Barcellini, Andrea Patriarca, Elena Rivolti, Ugo Consoli, Silvia Cantoni, Esther Natalie Oliva, Federico Chiurazzi, Giovanni Caocci, Gaetano Giuffrida, Alessandra Borchiellini, Giuseppe Auteri, Erminia Baldacci, Giuseppe Carli, Daniela Nicolosi, Emanuele Sutto, Monica Carpenedo, Michele Cavo, Maria Gabriella Mazzucconi, Francesco Zaja, Valerio De Stefano, Francesco Rodeghiero, Nicola Vianelli

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
2 Followers
0 Following